Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Physical Geography, Baku State University, Baku, Azerbaijan.
Biomed Res Int. 2021 Oct 14;2021:9318725. doi: 10.1155/2021/9318725. eCollection 2021.
The coronavirus disease 2019 (COVID-19) pandemic poses a special risk for both immunosuppressed patients, especially transplant recipients. Although the knowledge about this infection is growing, many uncertainties remain, particularly regarding the kidney. Kidney transplant recipients (KDRs) should be considered immunocompromised hosts since a potential risk for infection, comorbidity, and immunosuppression exposure exists. Additionally, the management of immunosuppressive agents in KDRs remains challenging. Potential drug interactions with immunosuppressive treatment escalated the risk of unwanted side effects. In this review, we aimed to attain an augmented awareness and improved management immunosuppressant for COVID-19 KDRs.
2019 年冠状病毒病（COVID-19）大流行对免疫抑制患者，尤其是移植受者构成特殊风险。尽管有关这种感染的知识在不断增加，但仍存在许多不确定性，特别是在肾脏方面。肾移植受者（KDR）应被视为免疫功能低下的宿主，因为存在感染、合并症和免疫抑制暴露的潜在风险。此外，KDR 中免疫抑制剂的管理仍然具有挑战性。免疫抑制治疗的潜在药物相互作用增加了不良副作用的风险。在本综述中，我们旨在提高对 COVID-19 KDR 免疫抑制剂的认识并改善其管理。
